Iveta Kudaba

Medicine & Life Sciences

1. pembrolizumab 100%
2. Drug Therapy 57%
3. Stomach Neoplasms 54%
4. Phase IV Clinical Trials 54%
5. atezolizumab 50%
6. pertuzumab 49%
7. Placebos 44%
8. Erlotinib Hydrochloride 40%
9. Phase III Clinical Trials 38%
10. Safety 37%
11. Trastuzumab 37%
12. Organized Financing 37%
13. Docetaxel 35%
14. Small Cell Lung Carcinoma 35%
15. Adenocarcinoma of Lung 33%
16. Non-Small Cell Lung Carcinoma 32%
17. ErbB Receptors 30%
18. Progression-Free Survival 27%
19. Albumins 27%
20. Ligands 26%
21. Etoposide 22%
22. Randomized Controlled Trials 21%
23. Breast Neoplasms 20%
24. Mutation 19%
25. Expert Testimony 16%
26. Mortality 15%
27. Therapeutics 14%
28. Survival 14%
29. Neoplasms 14%
30. Hematopoietic Stem Cells 10%
31. Esophagogastric Junction 10%
32. 4-nitrophenyl chloromethyl(phenyl)phosphinate 9%
33. Population 9%
34. Medicine 8%
35. Clinical Trials 7%
36. Neutropenia 7%
37. Intention 7%
38. Latvia 6%
39. Quality of Life 6%
40. Ilex 6%
41. Medical Writing 6%
42. Carboplatin 5%
43. Patient Reported Outcome Measures 5%
44. Stomach 5%
45. Hungary 5%
46. Conflict of Interest 5%